Clinical Trial Update: Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing fixed-dose QMF149 (150/80 µg) to MF Twisthaler (200 µg) in patients with mild asthma; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• MF Twisthaler (mometasone furoate)
• QMF149 (mometasone/formoterol)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Mild Asthma | Phase 3 | Status: COMPLETED | Results posted: 2019-09-12